CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced new preclinical data supporting that its lead candidate, galeterone (TOK-001) may represent the next-generation of therapy for patients with castration-resistant prostate cancer (CRPC) and disease that has progressed despite treatment with enzalutamide (Xtandi®). These data were presented today in a poster presentation titled, “Galeterone Suppresses Castration-Resistant and Enzalutamide-Resistant Prostate Cancer Growth in Vitro,” abstract number C89, at the AACR-NCI-EORTC 2013 International Conference on Molecular Targets and Cancer Therapeutics in Boston.
Help employers find you! Check out all the jobs and post your resume.
